Amgen (AMGN) Share-based Compensation (2009 - 2026)

Amgen's Share-based Compensation history runs 14 years deep, the most recent figure standing at $75.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 11.76% year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $484.0 million (down 5.47% YoY), while the FY2025 annual figure was $494.0 million, down 6.79% from the prior year.
• Share-based Compensation was $75.0 million for Q1 2026 at Amgen, down from $125.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $161.0 million in Q4 2023 to a low of $47.0 million in Q1 2023.
• Historically, Share-based Compensation has averaged $117.7 million across 4 years, with a median of $125.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 119.15% in 2024, then decreased 17.48% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $161.0 million in 2023, then slipped by 16.77% to $134.0 million in 2024, then retreated by 6.72% to $125.0 million in 2025, then slumped by 40.0% to $75.0 million in 2026.
• The last three Share-based Compensation figures came in at $75.0 million (Q1 2026), $125.0 million (Q4 2025), and $127.0 million (Q3 2025), per Business Quant data.